These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10051763)

  • 1. Inducing placebo respiratory depressant responses in humans via opioid receptors.
    Benedetti F; Amanzio M; Baldi S; Casadio C; Maggi G
    Eur J Neurosci; 1999 Feb; 11(2):625-31. PubMed ID: 10051763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems.
    Amanzio M; Benedetti F
    J Neurosci; 1999 Jan; 19(1):484-94. PubMed ID: 9870976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How the doctor's words affect the patient's brain.
    Benedetti F
    Eval Health Prof; 2002 Dec; 25(4):369-86. PubMed ID: 12449081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression.
    Benedetti F; Amanzio M; Baldi S; Casadio C; Cavallo A; Mancuso M; Ruffini E; Oliaro A; Maggi G
    Pain; 1998 Apr; 75(2-3):313-9. PubMed ID: 9583767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opiate receptor pharmacology: mixed agonist/antagonist narcotics.
    Hameroff SR
    Contemp Anesth Pract; 1983; 7():27-43. PubMed ID: 6136392
    [No Abstract]   [Full Text] [Related]  

  • 7. Opioid-induced respiratory effects: new data on buprenorphine.
    Dahan A
    Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
    La Vincente SF; White JM; Somogyi AA; Bochner F; Chapleo CB
    Clin Pharmacol Ther; 2008 Jan; 83(1):144-52. PubMed ID: 17568402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide and nonpeptide ligands for opioid receptors.
    Misicka A
    Acta Pol Pharm; 1995; 52(5):349-63. PubMed ID: 8960271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.
    Spivak CE; Beglan CL; Seidleck BK; Hirshbein LD; Blaschak CJ; Uhl GR; Surratt CK
    Mol Pharmacol; 1997 Dec; 52(6):983-92. PubMed ID: 9415708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential cardiovascular and respiratory responses to central administration of selective opioid agonists in conscious rabbits: correlation with receptor distribution.
    May CN; Dashwood MR; Whitehead CJ; Mathias CJ
    Br J Pharmacol; 1989 Nov; 98(3):903-13. PubMed ID: 2556206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic/opioid interaction in anterior cingulate cortex reduces the nociceptive response of vocalization in guinea pigs.
    Zugaib J; Menescal-de-Oliveira L
    Brain Res; 2017 Sep; 1671():131-137. PubMed ID: 28736107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naloxone reversal of buprenorphine-induced respiratory depression.
    Gal TJ
    Clin Pharmacol Ther; 1989 Jan; 45(1):66-71. PubMed ID: 2491980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
    Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous opiates and behavior: 2014.
    Bodnar RJ
    Peptides; 2016 Jan; 75():18-70. PubMed ID: 26551874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
    Stinus L; Cador M; Zorrilla EP; Koob GF
    Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo and opioid analgesia-- imaging a shared neuronal network.
    Petrovic P; Kalso E; Petersson KM; Ingvar M
    Science; 2002 Mar; 295(5560):1737-40. PubMed ID: 11834781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice.
    Skoubis PD; Matthes HW; Walwyn WM; Kieffer BL; Maidment NT
    Neuroscience; 2001; 106(4):757-63. PubMed ID: 11682161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid receptors on bulbospinal respiratory neurons are not activated during neuronal depression by clinically relevant opioid concentrations.
    Stucke AG; Zuperku EJ; Sanchez A; Tonkovic-Capin M; Tonkovic-Capin V; Mustapic S; Stuth EA
    J Neurophysiol; 2008 Nov; 100(5):2878-88. PubMed ID: 18815346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissection of placebo analgesia in mice: the conditions for activation of opioid and non-opioid systems.
    Guo JY; Wang JY; Luo F
    J Psychopharmacol; 2010 Oct; 24(10):1561-7. PubMed ID: 19395430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.